ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors by Vargas, G. et al.
This is a repository copy of ERRα promotes breast cancer cell dissemination to bone by 
increasing RANK expression in primary breast tumors.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/155723/
Version: Accepted Version
Article:
Vargas, G., Bouchet, M., Bouazza, L. et al. (22 more authors) (2019) ERRα promotes 
breast cancer cell dissemination to bone by increasing RANK expression in primary breast
tumors. Oncogene, 38 (7). pp. 950-964. ISSN 0950-9232 
https://doi.org/10.1038/s41388-018-0579-3
This is a post-peer-review, pre-copyedit version of an article published in Oncogene. The 
final authenticated version is available online at: 
http://dx.doi.org/10.1038/s41388-018-0579-3.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
 1 
ERRα  promotes breast cancer cell dissemination to bone by increasing 
RANK expression in primary breast tumors 
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Precis:  
Our work suggests that ERRα/RANK expression in primary tumors is a predictive marker of 
the occurrence of bone metastases in breast cancer patients.  
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Abstract  
Bone is the most common metastatic site for breast cancer. Estrogen-related receptor alpha 
(ERRα) has been implicated in cancer cell invasiveness. Here, we established that ERRα 
promotes spontaneous metastatic dissemination of breast cancer cells from primary 
mammary tumors to the skeleton. We carried out cohort studies, pharmacological inhibition, 
gain-of-function analyses in vivo and cellular and molecular studies in vitro to identify new 
biomarkers in breast cancer metastases. Meta-analysis of human primary breast tumors 
revealed that high ERRα expression levels were associated with bone but not lung 
metastases. ERRα expression was also detected in circulating tumor cells from metastatic 
breast cancer patients. ERRα overexpression in murine 4T1 breast cancer cells promoted 
spontaneous bone micro-metastases formation when tumor cells were inoculated 
orthotopically, whereas lung metastases occurred irrespective of ERRα expression level. 
RANK was identified as a target for ERRα in vivo and in ERRα−overexpressing breast 
cancer cells, RANKL stimulated tumor cell invasion and signalling pathways including 
mTOR phosphorylation in vitro. Pharmacological inhibition of ERRα reduced primary tumor 
growth, bone micro-metastases formation and RANK expression in vitro and in vivo. 
Transcriptomic study and meta-analysis confirmed a positive association between metastases 
and ERRα/RANK in primary breast tumors and also revealed a positive correlation between 
ERRα and BRCA1
mut
 carriers. Taken together, our results reveal a novel ERRα/RANK axis 
by which ERRα in primary breast cancer promotes early dissemination of cancer cells to 
bone. These findings suggest that ERRα may be a useful therapeutic target to prevent bone 
metastases. 
 4 
Abbreviations used in this paper: ANOVA: analysis of variance; BCa: Breast Cancer; BM: 
Bone metastases; CTC: Circulating Tumor Cells; ERR: Estrogen-Related Receptor; FP: Fat 
Pad; RANKL: Receptor Activator of Nuclear factor kB ligand; IHC: immunohistochemistry; 
LM: Lung Metastases; PBT: Primary Breast Tumors; RANK: RANKL receptor; RT: Reverse 
Transcription; PCR: Polymerase Chain Reaction; TCB: Tumor cell Colonization of Bone; 
Vegf: Vascular endothelial growth factor. 
  
 5 
Introduction  
Metastases are the primary cause of death (1) and in breast cancer (BCa), bone is the most 
common metastatic site (2). Bone metastases (BM) detection often occurs in the symptomatic 
stage and when they are diagnosed, the prognosis for the patient is generally poor and 
associated with significant morbidity. Unfortunately, current treatments for BM that rely on 
anti-resorptive agents are only palliative underlining the need of early detection of BM for 
early intervention (3)(4)(5).  
Nuclear steroid receptors are transcription factors that comprise both ligand-dependent 
molecules such as estrogen receptors (ERs) and a large number of so-called orphan receptors, 
for which no natural ligands have yet been identified (6). The estrogens-related receptor 
alpha (ERRα) shares structural similarities with ERα/β, but it does not bind estrogens (6). 
Indeed, sequence alignment of ERRα and the ERs reveals a high similarity (68%) in the 66 
amino acids of the DNA binding domain, but only a moderate similarity (36%) in the ligand-
binding domain, which may explain the fact that ERRα recognizes the same DNA binding 
elements as ERs but does not bind oestrogens (7). Although ERRα activity is decreased by 
synthetic molecules such as the inverse agonists XCT790 or C29, no natural ligand has yet 
been found (8)(9).  
ERRα is known to regulate fatty acid oxidation and the adaptive bioenergetics response (10).  
It is widely expressed in both healthy tissues and a range of cancerous cells (11)(12)(13). 
Notably, ERRα was found to be markedly increased in neoplastic versus normal tissues and 
ERRα-positive tumors were associated with more invasive disease and higher risk of 
recurrences (11)(13). In addition to angiogenesis, ERRα is mainly linked to tumor cells 
invasion (13)(14). ERRα is also highly expressed in skeletal tissues where it is known to 
regulate osteoblast and osteoclast differentiation and migration as well as bone remodelling 
in vitro and in vivo (15)(16)(17)(18). In BM, we have previously reported that overexpression 
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of ERRα in triple-negative BCa cells and castration-resistant prostate cancer cells results in 
either the inhibition or the activation of tumor cells progression in the bone 
microenvironment respectively (19)(20). Here, we assess whether ERRα expression in 
primary breast tumors (PBT) regulates the molecular mechanisms that drive BCa cell homing 
to bone. 
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Materials and Methods  
Ethics approval 
BALB/c female mice were purchased from Janvier and handled according to the French 
Ministerial Decree No.87-848 of 19 October 1987. Experimental protocols were approved by 
the Institutional Animal Care and Use Committee at the Universit Lyon 1 (France) (CEEA-
55 Comit dÕEthique en Exprimentation Animale DR2014-44;DR2015-28). Studies 
involving human primary specimens were carried out according to the principles embodied in 
the Declaration of Helsinki.  
Immunohistochemistry and Transcriptomic study on BCa patient primary tumor specimens.  
Immunohistochemistry (IHC) was performed on formalin-fixed paraffin-embedded tumor 
tissue sections (n=100) from the Austrian Breast and Colorectal Cancer Study Group 
(ABCSG) Trial 6 (21) (Supplementary Methods section). For IHC, a mouse monoclonal anti-
human/mouse ERRα antibody (1/50) (Santa Cruz) were used. To assess ERRα 
immunostaining, we used the H-score method (22). RT-PCR were performed and analyzed 
on specimens 446 from unilateral invasive PBT radically-resected BCa patients managed at 
Institut Curie-Hpital Ren Huguenin (France) (Supplementary-TableS1) selected to 
encompass the various stages of BCa progression (Supplementary Methods section) (23)(24). 
This study was approved by the review board and ethics committee of the institute (23).  
 
Detection of ERRα in circulating tumor cells (CTC) 
Blood of 60 metastatic BCa patients recruited at the Cancer Institute of Montpellier in 2017 
(Bioethics Committee D-RCB 2015-A00119-40) (Supplementary Methods section) was 
analyzed. Tumor cells were detected by using the Cellsearch¨ system (Silicon Biosystem, 
Menarini). For ERRα detection in CTCs, we used the 4
th
 channel of the CellSearch¨ and 
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anti-human ERRα/NR3B1 A488-conjugated polyclonal antibody (Novus, Littleton, USA) at 
a final concentration of 25 µg/mL.  
 
Meta-analysis of ESSRA expression 
Independent datasets of breast tumors for which microarray data were publicly available were 
analyzed: The BCa cohort ÒNKIÓ (Netherlands Cancer Institute, n=295) consisted of early-
stage tumors (50% lymph node negative) with the relapse status fully documented (25) and 
the ÒMETABRICÓ cohort of 2051 breast cancers (26) that was used to assess the correlation 
of BRCA mutations and ESRRA expression. For correlation analysis, published datasets were 
downloaded from the Gene-Expression-Omnibus including primary Tumors, Bone, Lung and 
Liver metastases (GSE14020) (27) and PBT, no-metastases, Visceral and bone or only bone 
metastases (GSE12276-GSE2034-GSE2603)(Supplementary-TableS2)(28)(29)(30). Methods 
for the processing are described in the Supplementary Methods section.  
 
Cell lines, transfection and immunoblotting 
Human MCF7 (Year 2012) and mouse 4T1(Year 2012) mammary cancer cell lines were 
obtained from the American Type Culture Collection. The human BC-M1 cell line  (generous 
gift from the Dr K Pantel lab) was obtained from a bone marrow aspirate of a BCa patient 
with no clinical signs of distant metastases at the time of the primary tumor resection 
(31)(32). Different conditions were used for culture (Supplementary Methods section). 
Murine and human ERRα cDNA (ERRα) and the dominant-negative form mutated into the 
co-activator domain AF2 (AF2) were prepared previously (19)(20) and transfected into 4T1 
or MCF7 cells (Supplementary Methods section). Parental 4T1 and MCF7 cells were treated 
with the ERRα inverse-agonist C29 at 5µM and 1-5µM respectively for 48h (9)(33). DMSO 
was used as vehicle. For Rank studies, 4T1-CT (pool of 2 clones), 4T1-ERRα (pool of 3 
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clones) were plated at 5x10
5
 cells/well with complete medium. The next day, cells were 
starved for 24 hours and then treated with Rankl (50ng/mL) (R&D) for different times (0-5-
15-25 min). Proteins extraction and immunoblotting was performed as described previously 
(19)(20) (Supplementary Methods section).  
Animal studies 
BALB/c female mice, 6 weeks of age, were housed in barrier conditions under isolated 
laminar flow hoods. Mice bearing tumor xenografts were closely monitored for established 
signs of distress and discomfort and were humanely euthanized. Tumor fat pad (FP) 
experiments were performed using the 4T1-CT (pool of 2 clones), 4T1-ERRα (pool of 3 
clones) or 4T1-AF2 (pool of 3 clones) cell lines (10
5
 cells in 10µL of PBS) injected into FP 
of the 4th mammary gland of mice as described previously (34)(Supplementary Methods 
section).  
FP experiments were also performed using 4T1-ERRα cells (pool of 3 clones) (10
5
 cells in 
10µL of PBS). When primary tumors reached approximately 30mm
3
, mice were randomized, 
treated every two days for 10 days by intra-peritoneal injection with vehicle (DMSO 10%, 
30% PEG) or C29 (10mg/kg) (9)(35), then prepared and analyzed as above.  
 
Immunohistochemistry on mice PBT sections  
IHC analysis was performed by incubating 5µm paraffin sections overnight with mouse 
monoclonal anti-human/mouse RANK (1/50) (Abcam), and a mouse monoclonal anti-
human/mouse ERRα antibody (1/50) (Santa Cruz) (19). Sections were then incubated with 
horseradish peroxidase (HRP)-conjugated anti-mouse (Dako) antibodies for 1hour and 
stained using 3,3Õ-diaminobenzidine (Dako). Counterstaining was performed using MayerÕs 
hematoxylin (Merck). 
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Cell migration assay 
Migration assays were carried out using the HTS FluoroBlok
TM
 Multiwell Insert System 
(Corning) 8 µm transwells as described previously (19). After 12 hours of starvation, 4T1-CT 
(2 clones) and 4T1-ERRα (3 clones) (5x10
4 
cells) were plated in the upper chambers and the 
chemoattractant (0.5% FBS) with or without Rankl (50ng/mL) (R&D) in the lower chambers. 
After 12 hours at 37¡C in 5% CO2 incubator, cells that had migrated through the filters were 
fixed, stained with DAPI (Life Technologies) and counted. All experiments were run in 
triplicate, and migration was expressed in % of migration/wells. 
 
Real time RT-PCR on cell lines and mice PBT specimens mRNA  
Total RNA was extracted with Trizol reagent (Life Technologies) and 2µg was reverse-
transcribed using SuperscriptTM II (Life-Technologies) (20). Real-time PCR was performed 
on a Mastercycler-ep-Realplex (Eppendorf) with primers specific to human and mouse genes 
(Supplementary Table S1) using Quantifast SYBR Green (Life-Technologies). PCR was 
carried out according to the manufacturerÕs instructions (20). Relative gene expression levels 
were normalized according to the Ct value of the housekeeping gene encoding the ribosomal 
protein L32 and results were expressed as fold differences equal to 2
-
ΔΔ
Ct
.  
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software (San Diego,USA). Data 
were analyzed statistically by the non-parametric Mann-Whitney U test or unpaired t-test for 
in vivo studies. In vitro data were analyzed using ANOVA and Student t-test to assess the 
differences between groups. Metastases-free survival (MFS), Lung metastases-free survival 
(LMFS) and Bone metastases-free survival (BMFS) was determined as the interval between 
diagnosis and detection of the first metastases. Survival distributions was estimated by the 
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Kaplan-Meier method, and the significance of differences between survival rates was 
ascertained using the log-rank test. For all statistical tests, differences was considered 
significant at confidence levels greater than 95% (p < 0.05). 
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Results  
 
High ERRα protein expression levels in primary tumors are associated with bone relapse in 
BCa patients  
We assessed ERRα protein expression levels in primary tumors from patients of the ABCSG 
trial 6 cohort, which is a prospective, randomized clinical study for postmenopausal patients 
with hormone receptor-positive early-stage BCa, treated with tamoxifen-aminoglutethimide 
and followed for up to 15 years (21). Kaplan-Meier analysis of distant-recurrence-free 
survival stratified by ERRα protein expression level (high) (Fig.1Bb) or (low) (Fig.1Ba) 
showed that high levels of ERRα protein expression (Fig.1A) correlated with lower distant 
recurrence-free survival (%) (n=100). To further examine ERRα pathophysiologic relevance 
in breast tumor cells, we then asked if ERRα is expressed in circulating tumor cells (CTCs) 
from metastatic BCa patients. After establishing conditions for ERRα detection using cell 
lines (Supplementary Fig.S1), ERRα expression was detected in CTCs in three out of 60 
patients with metastatic BCa (Fig.1C), further supporting the hypothesis that ERRα present in 
CTCs may be involved in the metastatic process. We, therefore, next analyzed the ERRα 
transcriptional profile in the NKI-295 cohort that includes 295 radically-resected primary 
BCa from patients (under 53 years) with known location of the first distant metastatic site 
(25). ERRα expression level was positively associated with histological grade and lymph 
node status (Supplementary Table S3A). Univariate Cox proportional hazard model analysis 
indicated that ERRα expression is associated with metastases-free survival (MFS) and bone 
metastases free-survival (BMFS) but not with lung metastases free-survival (LMFS) 
(Supplementary Table S3B). Furthermore, Kaplan Meier curves demonstrated that high 
ERRα expression is correlated with a decrease in BMFS but not LMFS (Fig.1DE). Notably, 
neither ERRβ nor ERRγ mRNA expression levels correlated with MFS, BMFS or LMFS 
(Supplementary Table S3B).  
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ERRα in BCa cells promotes spontaneous bone micro-metastases formation in vivo 
To assess the role of ERRα in the early steps of metastatic dissemination of BCa, we used the 
murine 4T1 BCa cell line, from which cells spontaneously metastasize from primary tumor to 
lung and bone (36). Three independent 4T1 clones overexpressing ERRα (clones 1-3), three 
4T1-AF2 clones (1-3) which act as a dominant-negative form, and two empty vector controls 
4T1-CT (1-2) were isolated. Western blots confirmed that the ~54kD ERRα protein band was 
increased in 4T1-ERRα (1-3) compared to 4T1 CT1-2 cells (Fig.2A) and that a band with 
slightly lower molecular weight, corresponding to the expected size for truncation of the AF2 
domain (42aa), was present in 4T1-AF2 (1-3) cells (Supplementary Fig.S2A).  
Analysis of primary mammary gland FP tumors in mice, orthotopically inoculated with 4T1-
CT, 4T1-ERRα or 4T1-AF2 cells, indicated greater tumor progression in 4T1-ERRα-FP 
tumour-bearing animals compared to 4T1-CT-FP (Fig.2B-D) and 4T1-ERRαAF2-FP 
(Supplementary Fig.S2BC). In agreement with previous data (37), we found that Vegf-a 
expression was significantly increased in 4T1-ERRα-FP tumors (Supplementary Fig.S2DE).  
Culturing cells collected from crushed bones of mice kept for an additional 21 days post-
primary tumor resection and counting colonies (38) revealed greater tumor cell colonization 
of bone (TCB) by 4T1-ERRα-FP (Fig.2E), with higher incidence of dissemination to bone 
with 4T1-ERRα cells (77%) compared to 4T1-CT cells  (12%)(Fig.2F) and a higher number 
of TCB (Fig.2G). In contrast, histological assessment of lung metastases (LM) revealed no 
difference in the number or incidence of lung colonies (Fig.2H-J) or metastases surface 
between both groups, in spite of maintenance of ERRα overexpression in 4T1-ERRα-LM 
versus 4T1-CT-LM (Supplementary Fig.S2FG). Taken together, these pre-clinical data 
confirm a correlation between ERRα expression level and BMFS but not LMFS 
(Fig.1DE;Supplementary Table S3B). 
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ERRα regulates RANK expression in BCa cells  
To explore the underlying mechanism responsible for the ability of 4T1-ERRα cells to 
promote homing of cancer cells to bone in vivo, we quantified in PBT transcriptional 
expression levels of several markers involved in bone tropism. Expression of Receptor 
Activator of Nuclear Factor κ B  (RANK) was stimulated in vivo in 4T1-ERRα-FP (Fig.3A) 
(39)(40)(41). In contrast, no effect was observed on the expression of Cxcr4 mRNA, also 
involved in cancer cell bone but also in lung tropism (Fig.3A). Rank protein expression was 
also higher in 4T1-ERRα-FP tumors (Fig.3Bb). RANK regulation by ERRα was confirmed in 
a second human BCa cell line, MCF7, which we also engineered to overexpress full-length 
(wild type; MCF7-ERRα) or truncated (MCF7-ERRαAF2) human ERRα compared to the 
empty vector control (MCF7-CT) (Fig.3CD).  The ERRα inverse agonist C29 (9)(33) which 
blocks ERRα transcriptional activity (Fig.3EF and H) also inhibited RANK mRNA 
expression in 4T1 and MCF7 parental cells (Fig.3GI). Using the human BC-M1 disseminated 
tumor cell (DTC) line established from the bone marrow of a breast cancer patient (31), we 
also demonstrated ERRα and RANK mRNA co-expression (Fig.3J). More importantly, 
expression of both ERRα and RANK mRNA was stimulated when BC-M1 cells were cultured 
under low O2 conditions compared with normoxia.  
To determine whether Rank stimulation has functional consequences, 4T1-ERRα cells 
(clones 1-3) were subjected to migration assays with and without Rankl treatment. Rankl 
significantly stimulates migration of 4T1-ERRα cells (4T1-ERRα versus 4T1-ERRα+Rankl) 
but not 4T1-CT cells (Fig.4AB). Unexpectedly, the migratory ability of untreated 4T1-
ERRα cells was lower than that of untreated 4T1-CT cells but this was reversed by Rankl 
treatment (Fig.4B), revealing the high sensitivity of 4T1-ERRα cells to Rankl. Reinforcing 
the view that ERRα regulates Rankl signalling, we observed a more marked increase in 
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mTOR phosphorylation (at 5 to 25 min) and lesser increase in pSrc (25 min) and pAkt (15 
min) in Rankl-treated 4T1-ERRα cells compared to 4T1-CT cells (Fig.4CD) (39).  
Pharmacological inhibition of ERRα reduces mammary tumor growth, bone marrow micro-
metastases formation and RANK expression in vivo 
To determine whether inhibition of ERRα  abrogates PBT progression and BCa cell 
dissemination to bone, BALB/c female mice were inoculated orthotopically into the 
mammary gland FP with 4T1-ERRα cells (clones 1-3) and treated with the ERRα  inverse 
agonist C29 or with vehicle from the time of tumor appearance to tumor resection. Tumor 
weight/volume was reduced in 4T1-ERRα-FP tumor-bearing animals treated with C29 
(Fig.5A-C). No toxicity from the C29 treatment was seen (Supplementary Fig.S3A-D). TCB 
were reduced in C29-treated mice (Fig.5DE). No difference was observed between colony 
numbers corresponding to tumor cells that disseminated to lung in C29 treated mice 
(Supplementary Fig.S3E). ERRα and Rank mRNA expression was inhibited in PBT of C29-
treated (Fig.5F). Similarly, ERRα and Rank proteins level (Supplementary Fig.S4AB) was 
reduced in PBT in C29-treated mice. 
ERRα /RANK link in BCa patients who developed bone metastases 
Meta-analysis of the PBT GSE14020 dataset (27) confirmed a positive association of ERRα 
and RANK in patients who developed bone metastases but not in patients who developed lung 
and liver metastases (Table.1A). Moreover, in the Curie Institute cohort (n=446) stratification 
of BCa patients into subtypes showed positive correlation between ERRα and RANK in Triple 
Negative patients (NNN) and Luminal BCa patients (HR
+
ERBB2) but not ERBB2+ patients 
(HR- and HR+) (Table.1B; Supplementary Table S4) (23). No correlation was observed 
between ERRα and RANKL (TNFSF11). In line with these data, we also found that 
expression levels of ERRα and RANK were positively correlated in primary BCa samples 
(HR+ERBB2-) in combined microarray datasets GSE12276, GSE2034 and GSE2603 
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(Table.1C; Supplementary Table S2). The strongest correlation was observed in patients who 
had developed only bone metastases and no correlation was observed in non-metastatic 
patients (No Mets).  
ERRα is highly expressed in PBT from BRCA1-mutated carriers  
Recently, RANK/RANKL were shown to control BRCA1 mutation-driven mammary tumor 
formation and progressions (42). We therefore next asked whether ERRα and BRCA1 
expression are correlated. Using the combined microarray datasets GSE12276, GSE2034 and 
GSE2603, we found a positive correlation between ERRα  and BRCA1 in PBT in patients 
who had developed both visceral+bone and only bone metastases, and with BRCA2 
expression in patients with metastases at all sites (Table.1C). Since these datasets were not 
informative on the BRCA1 and 2 mutations status, we used the METABRIC cohorts that 
include 2051 radically-resected primary BCa, where BRCA1
mut
 or 2
mut
 were identified. ERRα 
expression level was higher in BRCA1
mut
 carriers but not BRCA2
mut
-carriers compared to 
those with no mutations (Fig.6).  
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Discussion 
Our findings indicate that ERRα  can be expressed in CTCs and promotes BCa cell homing to 
bone. The identification of RANK as an ERRα-regulated gene in our pre-clinical 4T1 cell 
model and ERRα/RANK positive association in BCa patient cohorts provide new mechanistic 
insights into ERRα-regulated pathways mediating early BCa cell invasion of bone. 
Elevated ERRα expression has been observed in various tumor samples and associated with 
tumor aggressiveness (13). More recently, ERRα expression has been linked to resistance to 
several therapies including lapatinib, mTOR inhibitors and endocrine therapies such as 
tamoxifen (43) (44) (45). The high expression of ERRα that we documented in patient 
cohorts, including the ABCSG trial 6 cohort treated with tamoxifen with or without 
aminoglutethimide, supports the view that ERRα may be used as a prognosis factor in 
endocrine therapy responses at an early stage of PBT. Moreover, the fact that we have 
observed ERRα expression in CTCs of BCa metastatic patients and documented changes in 
BCa cell migration with changes in ERRα activity further strengthens the notion that ERRα 
may be involved into CTCs survival and metastases.  
We also show that high level of ERRα  was associated with bone but not with lung 
metastases in our mouse experimental model of spontaneous metastatic BCa and in the BCa 
patient cohorts. With respect to bone homing, our identification of RANK as a new 
ERRα−regulated gene is notable. RANK, the cognate receptor of RANKL, is highly 
expressed in carcinomas and is considered as a poor prognostic marker in BCa (46). RANK 
expression was also described as being predictive of poor prognosis in bone metastases 
patients but not in patients with visceral metastases (40) (41) (46).  One explanation comes 
from evidence that RANKL is a chemoattractant: RANKL produced by osteoblasts and bone 
marrow stromal cells has been shown to attract RANK-expressing cancer cells and induce 
their migration in the bone microenvironment. This mechanism has been observed not only in 
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BCa but also in other cancers (41). Activation of RANK by RANKL is known to activate 
several signalling cascades including Src, ERK, Akt/mTOR and concomitantly to stimulate 
cancer cell migration, survival and protein synthesis (39). More recently, transgenic mice 
overexpressing RANK in mammary glands were reported to develop pre-neoplastic foci, 
suggesting that RANK may promote the initial stage of BCa development (47)(48). 
Moreover, the RANK/RANKL axis has recently been shown to be critical regulators of 
BRCA1-mutation-driven BCa and anti-RANKL therapy is now proposed as a preventive 
strategy for women carrying BRCA1 mutations (42)(49). Based on RANK functions and our 
new findings, ERRα appears to be a potentiel  new player in the RANK/RANKL axis and 
BCa cancer occurrence and progression. Indeed, we demonstrated up- or downregulation of 
RANK expression in BCa cells after stimulation (overexpression) or pharmacologic 
inhibition (C29) respectively of ERRα in vivo and in vitro. Concomitant with the increase of 
RANK expression, we demonstrated stimulation of migratory capacity and activation of 
phosphorylation of mTOR, Src and Akt in BCa cells overexpressing ERRα. We also 
documented correlation of ERRα expression with occurrence of bone metastases but not with 
visceral or lung metastases in mice and in patients, suggesting that ERRα/RANK expression 
in primary tumors may be a predictive marker of bone metastases occurrence in BCa patients. 
Additionally, we found a significant correlation between high ERRα and BRCA1
mut
 in 
BRCA1
mut
 carriers, implying that ERRα may participate in the RANKL/RANK control of 
progenitor cell expansion and tumorigenesis in inherited breast cancer. Similarly to the 
suggestion that inhibition of the RANKL/RANK axis may be a therapeutic target for 
BRCA1
mut
 carriers, inhibition of an upstream RANK regulator, ERRα, may also constitute a 
useful new therapeutic approach for these patients (50).  In conclusion, we report for the first 
time a RANK/ERRα axis in BCa that contributes new mechanistic understanding of the 
overall negative outcome associated with ERRα in breast cancer.  
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Legends 
 
Fig.1: ERRα is a bone metastases-associated gene in BCa. (A) Kaplan-Meier curves show 
correlation between high expression of ERRα, categorized with median value, and distant 
recurrence-free survival in patients treated with tamoxifen alone or aminoglutethimide with 
tamoxifen (n=100). (B) Visualization of ERRα protein expression at low (a) and high level 
(b) by IHC on sections of PBT.  (C) Representative EpCAM(+), pan-keratin(+) (K-PE), CD45(-) 
CTCs and ERRα-AF488(+)/(-) from metastatic BCa patients detected by the CellSearch¨ 
System. DAPI was used for nuclear counter staining. (D) Kaplan-Meier curves constructed 
after segmentation into two groups on the basis of the median value for ERRα expression 
show correlation between high expression of ERRα and lower bone metastases free-survival 
(BMFS) in NKI cohort (n=295, P=0.01); Low ≤ 50% quartile; high ≥ 50%. (E) No 
correlation was found between high level of ERRα and lung metastases free-survival 
(LMFS).  
 
Fig.2: ERR promotes BCa cell homing to bone in vivo. (A) Three independent clones 
(4T1-ERRα 1-3) overexpressing full-length ERRα and two control clones with empty vector 
(4T1-CT 1-2) were obtained after stable transfection of 4T1 cells. ERRα (~54kD) expression 
was assessed by Western blotting and compared to α-tubulin as a protein loading control. (B) 
4T1-ERRα (pool of 3 clones) or 4T1-CT (pool of 2 clones) cells were inoculated into the 
mammary gland fat pad of BALB/c mice. Greater tumor expansion was observed in mice 
with 4T1-ERRα-FP (C-D) Weight and volume of tumors dissected at endpoint (n=10, Mann-
Whitney, weight: P=0.0156; volume: P=0.0074). (E) After resection, animals were kept for 
21 days, bones were then crushed and released cells were cultured for 3 weeks. (F, G) 
Counting of tumor cells that colonized the bone (TCB) revealed a high incidence with 4T1-
ERRα cells which was associated with an increase in TCB number (n=9, 262±175 versus 
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32±55, Mann-Whitney, P=0.0083). (H-J) Histological assessment of lung metastases (LM) 
(H) shows no difference between LM incidence (I) and LM number/lungs (J) (n=9).  
Asterisk represents lung metastases. 
 
Fig.3: Correlation between ERRα  and Rank expression in BCa cells. (A) Real-time PCR 
performed on mRNA extracted from 4T1 primary tumors confirmed increased expression of 
ERRα in 4T1-ERRα-FP and show increased expression of Rank by ERRα (ANOVA: 
P<0.0001 and unpaired t-test P<0.0001 for both ERRα and Rank). Cxcr4 mRNA expression 
was not altered. (B) Increased expression of Rank was visualized by IHC in 4T1-ERRα-FP 
(b) compared to 4T1-CT-FP (a). (C) MCF7 clones overexpressing ERRα or ERRαAF2 were 
obtained after retroviral transfection. ERRα overexpression was assessed by Western blotting 
and comparison to α-tubulin. (D) Real-time RT-PCR was performed on triplicate samples 
and normalized against the ribosomal protein gene L32 to evaluate ERRα and RANK 
expression (ANOVA: p<0.0001, unpaired t-test p<0.0001 for ERRα and ANOVA: p=0.0135, 
unpaired t-test p=0.0041 for RANK). (E-I) C29 treatment induced a decrease in Rank 
expression in both parental 4T1 and MCF7 cells lines. Inhibition of ERRα protein and 
mRNA induced by C29 at 5µM after 48h is shown by Western blotting and by real-time PCR 
(unpaired t-test, p<0.0001) respectively (E,F) concomitant with a decrease in Rank 
expression (unpaired t-test P=0.0419) (G) Inhibition of ERRα protein induced by C29 at 1 
and 5µM after 48h in MCF7 cells (H) is associated with a decrease of RANK mRNA 
expression (ANOVA: P=0.0016, unpaired t-test P=0.0127 and P=0.0062)(I). (J) Real-time 
PCR was performed on triplicate samples to evaluate ERRα and RANK expression in the BC-
M1 cells under low O2 conditions compared with normoxia. ERRα and RANK expression 
was higher under low O2 conditions (unpaired t-test P=0.0143 and P=0.0016 for ERRα  and 
RANK respectively). 
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Fig.4: Increased migration capacity of BCa cells overexpressing ERRα  after Rankl 
treatment. (A, B) Migration was increased in 4T1-ERRα cells (clones 1-3) after Rankl 
treatment (50ng/ml) for 12h (4T1-ERRα versus 4T1-ERRα+Rankl: ANOVA: P=0.0005, 
unpaired t-test P=0.0001). The percentage of migration of 4T1-CT cells (clones1-2) was 
unchanged after Rankl treatment (4T1-CT versus 4T1-CT+Rankl). In the absence of added 
RankL, migration of 4T1-ERRα cells was lower than that of 4T1-CT cells (P=0.0019), but 
the opposite was observed after Rankl treatment (P=0.002: 4T1-CT+Rankl versus 4T1-
ERRα+Rankl). (C) Rankl signalling was assessed by treating 4T1-ERRα cells (clones1-3) 
and 4T1-CT cells (clones1-2) cells with RankL for different times (0, 5, 15, 25 min). 
Activation of Src, mTor and Akt (pSrc, pmTor and pAkt) was assessed with α-tubulin as 
loading control. (D) mTor was markedly activated in 4T1-ERRα  cells at 5 min to 25min; Src 
and Akt were also stimulated in 4T1-ERRα cells but to a lesser extent than mTor at 25 min 
and 5 min respectively. 
 
Fig.5: Pharmacological inhibition of ERRα . (A) 4T1-ERRα (clones1-3) cells were 
inoculated into the FP of the mammary gland of BALB/c mice and mice were treated with 
C29 (10mg/kg) for 10 days from the time of tumor appearance to tumor resection (day 14). 
C29 (C29-Tumor-FP)(d-f) decreased tumor expansion compared to tumor growth in vehicle 
treated mice (a-c) (B, C) Weight and volume of tumors dissected at endpoint (n=9, unpaired 
t-test, weight: P=0.014; Mann and Whitney: volume: P=0.019). (D, E) After tumor resection, 
animals were kept for an additional 21 days, bones were then crushed and released cells were 
cultured for 3 weeks. C29 treatment (D-d-f; E) decreased TCB number compared Veh (D-a-
c; E) (n=5, 142 ±138 versus 416 ±138, unpaired t-test, P=0.035). (F) Real-time PCR 
performed on RNA extracted from C29 (C29-Tumour-FP) versus vehicle treated (Veh-
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Tumor-FP) mice  (n=3, unpaired t-test P=0.004 for ERRα and P=0.0032 for Rank) confirmed 
a decrease in the expression of ERRα and Rank in treated animals.  
 
Fig.6: Meta-analysis of the METABRIC cohorts that include 2051 radically-resected primary 
BCa, where BRCA1 and 2 mutations were identified, revealed correlation between high 
ERRα and BRCA1 mutation (Mann-Whitney P=0.02). No link was found between ERRα 
expression and BRCA2 mutation. 
 
Table.1: Correlation between ERRα  and Rank expression in BCa patients. (A) Meta-
analysis of the public dataset GSE14020 revealed correlation between ERRα and RANK in all 
tumors and in patients with bone but not lung or liver metastases. (B) Meta-analysis of the 
Curie BCa cohorts (n=446) revealed correlation between ERRα and RANK (TNFRSF11A) 
mRNA expression in the total tumor population, in the triple negative group and in the 
luminal group (HR+ERBB2-). No correlation was found in ERBB2+ patients (HR- and HR+) 
or with RANKL (TNFSF11). (C) Meta-analysis of public datasets GSE12276, GSE2034 and 
GSE2603 revealed correlation between ERRα and RANK, BRCA1 and BRCA2 expression 
levels in all tumors, in patients with visceral and bone metastases or only bone metastases.  
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